Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)
about
Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working PartyBrentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma.Nationwide Statistical Analysis of Lymphoid Malignancies in Korea.High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma.The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population-based retrospective study.
P2860
Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)
description
scientific article published on 26 July 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2012
@uk
name
Clinical features and outcomes ...... ng Survival of Lymphoma (CISL)
@en
Clinical features and outcomes ...... Improving Survival of Lymphoma
@nl
type
label
Clinical features and outcomes ...... ng Survival of Lymphoma (CISL)
@en
Clinical features and outcomes ...... Improving Survival of Lymphoma
@nl
prefLabel
Clinical features and outcomes ...... ng Survival of Lymphoma (CISL)
@en
Clinical features and outcomes ...... Improving Survival of Lymphoma
@nl
P2093
P2860
P1433
P1476
Clinical features and outcomes ...... ng Survival of Lymphoma (CISL)
@en
P2093
Cheolwon Suh
Dok Hyun Yoon
Hye Jin Kang
Hyeon-Seok Eom
Hyo Jung Kim
Jae-Yong Kwak
Jin Seok Kim
Jong-Ho Won
Joon Seong Park
P2860
P304
P356
10.1007/S00277-011-1297-X
P407
P577
2011-07-26T00:00:00Z